There is some evidence that hormone treatment may not result in a significant improvement in psychosocial functioning. It is estimated that it would cost US$100,000 or more to treat someone, but might only move them from the first percentile to perhaps the 10th. There is some ethical and economic concern whether such treatment would merely shift discrimination to the next most effected percentile. The use of insulin-like growth factor 1 or aromatase inhibitors have been proposed as an alternative to growth hormone. Advantage<unk>  stature decreases risk of venous insufficiency.
Idiopathic short stature
Psychosocial short stature
Constitutional growth delay
Congenital adrenal hyperplasia
Hypothyroidism
Isolated growth hormone deficiency
Micromegaly
Late onset congenital adrenal hyperplasia